Clinical Trial Update: Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial in pediatric patients with refractory or relapsed high-risk neuroblastoma and ganglioneuroblastoma is evaluating chemoimmunotherapy com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ganglioneuroblastoma
• Neuroblastoma

Drugs mentioned

• Chemoimmunotherapy
• autologous NK cell therapy (autologous natural killer cells)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Neuroblastoma (NB), Ganglioneuroblastoma | Phase 3 | Status: RECRUITING